nampt-in-5

Nampt-IN-5 is a potent and orally active inhibitor of nicotinamide phosphoribosyltransferase (NAMPT).

Nampt-IN-13 TFA is a NAMPT inhibitor (patent WO2021013693A1) suitable for synthesising antibody-drug conjugates (ADCs).

Namptactivator-5 (compound C8) is a potent activator of nicotinamide phosphoribosyltransferase (NAMPT), with a KD value of 6.19 µM. This compound demonstrates cellular anti-aging effects by promoting NAD+ production in the brain and reducing markers and secretory phenotypes associated with aging. Namptactivator-5 holds potential for researching age-related diseases.

GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.

Nampt-IN-10 TFA (compound 4) is a phosphoribosyltransferase (NAMPT) inhibitor with cellular efficacy against A2780 (IC50: 5 nM) and CORL23 (IC50: 19 nM), and can be used as a non-antimitotic payload for ADCs.

Nampt-IN-10 trihydrochloride (Compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor exhibiting cellular potency against A2780 and CORL23 cell lines, with IC50 values of 5 nM and 19 nM, respectively. It holds potential as a novel non-antimitotic payload for antibody-drug conjugate (ADC) [1].